Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer.
Wiseman CL, Holmes JP, Calfa C, Dakhil SR, Bhattacharya S, Peoples GE, Lacher MD, Lopez-Lago M, Kharazi A, Del Priore G, Chang M, Adams DL, Williams WV. Wiseman CL, et al. Among authors: lacher md. Hum Vaccin Immunother. 2024 Dec 31;20(1):2379864. doi: 10.1080/21645515.2024.2379864. Epub 2024 Aug 20. Hum Vaccin Immunother. 2024. PMID: 39165083 Free PMC article. Clinical Trial.
Regression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual Property and Immune Markers of Response.
Wiseman CL, Kharazi A, Sunkari VG, Galeas JL, Dozio V, Hashwah H, Macúchová E, Williams WV, Lacher MD. Wiseman CL, et al. Among authors: lacher md. Recent Pat Anticancer Drug Discov. 2022;18(2):224-240. doi: 10.2174/1574892817666220518123331. Recent Pat Anticancer Drug Discov. 2022. PMID: 35593340 Free PMC article. Clinical Trial.
SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes.
Lacher MD, Bauer G, Fury B, Graeve S, Fledderman EL, Petrie TD, Coleal-Bergum DP, Hackett T, Perotti NH, Kong YY, Kwok WW, Wagner JP, Wiseman CL, Williams WV. Lacher MD, et al. Front Immunol. 2018 May 15;9:776. doi: 10.3389/fimmu.2018.00776. eCollection 2018. Front Immunol. 2018. PMID: 29867922 Free PMC article.
Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes.
Funk WD, Labat I, Sampathkumar J, Gourraud PA, Oksenberg JR, Rosler E, Steiger D, Sheibani N, Caillier S, Stache-Crain B, Johnson JA, Meisner L, Lacher MD, Chapman KB, Park MJ, Shin KJ, Drmanac R, West MD. Funk WD, et al. Among authors: lacher md. Stem Cell Res. 2012 Mar;8(2):154-64. doi: 10.1016/j.scr.2011.10.001. Epub 2011 Oct 8. Stem Cell Res. 2012. PMID: 22265736 Free article.
17 results